LONDON – TauRx Therapeutics Ltd. said it has recruited the first patients to two Phase III Alzheimer's disease trials in which it aims to provide the first definitive proof that breaking down tangles of tau protein in the brain has a disease-modifying effect in the mild to moderate stages of pathology. Read More

LONDON – Initial tests of a new strategy aimed at killing the malaria parasite suggested that it may one day provide a fast and effective way of treating that infection. Read More

Sanofi SA, which reported third-quarter results last week, placed its pipeline challenges front and center, noting "business [earnings per share] reflects patent expirations." Read More

LONDON – Kymab Ltd. called up two industry veterans to help with the commercialization of its new platform technology for generating monoclonal antibodies in transgenic mice, as it prepares both to out-license access to the technology and use it to start an internal drug discovery effort. Read More

Three years after a new drug application was first submitted for leukemia drug omacetaxine mepesuccinate, during which the product moved twice into different hands via M&A transactions, the FDA granted a long-awaited nod Friday. Read More

• Domain Therapeutics SA, of Strasbourg, France, signed with Ono Pharmaceutical Co. Ltd., of Osaka, Japan, a collaboration agreement focused on discovering small molecules targeting G protein-coupled receptors. Read More